Monoclonal antibodies (MAbs) are immunologically active proteins, which bind specifically to certain cells or proteins. This stimulates the immune system to attack those targets. The importance of MAbs is becoming increasingly important for the treatment of different types of cancer and autoimmune diseases. Nowadays, a wide variety of therapeutic antibodies are available on the market and several more are in research and development.
Intact antibodies are usually analysed by IEX, SEC or HIC because of their high molecular weight (about 150 kDa). Mass spectrometry (MS) compatible RP methods have also become a useful tool. In the past, a lack of sensitivity and resolution has been a hurdle. With modern RP phases addressing the requirements of these analytes, it is now easier to find a suitable method.
Using a wide pore, temperature stable stationary phase such as YMC-Triart Bio C4, MAbs can be successfully analysed in RP mode. As a result of its extended stability, it is possible to use temperatures up to 90 °C.
This application note developed by Department of Analytical Pharmaceutical Chemistry, the University of Geneva demonstrates the robust chromatographic method using the commercially available MAbs: Ofatumumab (Arzerra®), Panitumumab (Vectibix®) and Palivizumab (Synagis®).
>> Download the full Application Note as PDF
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
